Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity

Toxicology

Volumn 289, Issue 2-3, 2011, Pages 122-131

  Hašková, Pavlína ^a   Koubková, Lucie ^a   Vávrová, Anna ^a   Macková, Eliška ^a   Hrušková, Kateřina ^a   Kovaříková, Petra ^a   Vávrová, Kateřina ^a   Šimůnek, Tomáš ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Catecholamine cardiotoxicity; Deferasirox (ICL670A); Deferiprone (L1); Desferrioxamine (DFO); Iron chelation

Indexed keywords

ADRENALIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; EDETIC ACID; IRON CHELATING AGENT; ISOPRENALINE; RAZOXANE;

ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CELL VIABILITY; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; HEART CELL CULTURE; HEART PROTECTION; HYDROPHILICITY; NONHUMAN; OXIDATIVE STRESS; PH; PRIORITY JOURNAL; RAT;

ANIMALS; CARDIOTONIC AGENTS; CARDIOTOXINS; CATECHOLAMINES; CELL LINE; IRON CHELATING AGENTS; MYOCYTES, CARDIAC; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS;

ANIMALIA;

EID: 80052769374     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2011.08.006     Document Type: Article

References (61)

1. Adameova A., Abdellatif Y., Dhalla N.S. Role of the excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease. Can. J. Physiol. Pharmacol. 2009, 87:493-514.
2. Al-Rousan R.M., Paturi S., Laurino J.P., Kakarla S.K., Gutta A.K., Walker E.M., Blough E.R. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil. Am. J. Hematol. 2009, 84:565-570.
3. Arozal W., Watanabe K., Veeraveedu P.T., Ma M., Thandavarayan R.A., Sukumaran V., Suzuki K., Kodama M., Aizawa Y. Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology 2010, 274:18-26.
4. Barnabe N., Zastre J.A., Venkataram S., Hasinoff B.B. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic. Biol. Med. 2002, 33:266-275.
5. Bendova P., Mackova E., Haskova P., Vavrova A., Jirkovsky E., Sterba M., Popelova O., Kalinowski D.S., Kovarikova P., Vavrova K., Richardson D.R., Simunek T. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem. Res. Toxicol. 2010, 23:1105-1114.
6. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 1991, 56:1441-1444.
7. Bolli R., Patel B.S., Zhu W.X., O'Neill P.G., Hartley C.J., Charlat M.L., Roberts R. The iron chelator desferrioxamine attenuates postischemic ventricular dysfunction. Am. J. Physiol. 1987, 253:H1372-H1380.
8. Chirnomas D., Smith A.L., Braunstein J., Finkelstein Y., Pereira L., Bergmann A.K., Grant F.D., Paley C., Shannon M., Neufeld E.J. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 2009, 114:4009-4013.
9. Costa V.M., Carvalho F., Bastos M.L., Carvalho R.A., Carvalho M., Remiao F. Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases. Curr. Med. Chem. 2011, 18:2272-2314.
10. Dean R.T., Nicholson P. The action of nine chelators on iron-dependent radical damage. Free Radic. Res. 1994, 20:83-101.
11. Dhalla N.S., Adameova A., Kaur M. Role of catecholamine oxidation in sudden cardiac death. Fundam. Clin. Pharmacol. 2010, 24:539-546.
12. Flandina C., Sanguedolce R., Rausa L., D'Alessandro N. Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse. Res. Commun. Chem. Pathol. Pharmacol. 1990, 70:259-272.
13. Galey J.B. Recent advances in the design of iron chelators against oxidative damage. Mini Rev. Med. Chem. 2001, 1:233-242.
14. Gerlo E.A., Sevens C. Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocytoma: diagnostic value in 19 cases. Clin. Chem. 1994, 40:250-256.
15. Goldstein D.S., Eisenhofer G., Kopin I.J. Sources and significance of plasma levels of catechols and their metabolites in humans. J. Pharmacol. Exp. Ther. 2003, 305:800-811.
16. Graf E., Mahoney J.R., Bryant R.G., Eaton J.W. Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site. J. Biol. Chem. 1984, 259:3620-3624.
17. Gujja P., Rosing D.R., Tripodi D.J., Shizukuda Y. Iron overload cardiomyopathy: better understanding of an increasing disorder. J. Am. Coll. Cardiol. 2010, 56:1001-1012.
18. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine 2007, Oxford University Press, Oxford, New York.
19. Hasinoff B.B. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovasc. Toxicol. 2002, 2:111-118.
20. Haskova P., Kovarikova P., Koubkova L., Vavrova A., Mackova E., Simunek T. Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autooxidation and cardiotoxicity. Free Radic. Biol. Med. 2011, 50:537-549.
21. Hershko C., Link G., Konijn A.M., Cabantchik Z.I. Objectives and mechanism of iron chelation therapy. Ann. N. Y. Acad. Sci. 2005, 1054:124-135.
22. Hoffbrand A.V., Cohen A., Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003, 102:17-24.
23. Jomova K., Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology 2011, 283:65-87.
24. Kalinowski D.S., Richardson D.R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 2005, 57:547-583.
25. Kell D.B. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch. Toxicol. 2010, 84:825-889.
26. Kimes B.W., Brandt B.L. Properties of a clonal muscle cell line from rat heart. Exp. Cell Res. 1976, 98:367-381.
27. Kovarikova P., Stariat J., Klimes J., Hruskova K., Vavrova K. Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites-the cardioprotectant dexrazoxane as a model case. J. Chromatogr. A 2011, 1218:416-426.
28. Kremastinos D.T., Farmakis D., Aessopos A., Hahalis G., Hamodraka E., Tsiapras D., Keren A. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ. Heart Fail. 2010, 3:451-458.
29. Lieu P.T., Heiskala M., Peterson P.A., Yang Y. The roles of iron in health and disease. Mol. Aspects Med. 2001, 22:1-87.
30. Lim C.K., Kalinowski D.S., Richardson D.R. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class. Mol. Pharmacol. 2008, 74:225-235.
31. Mladenka P., Hrdina R., Bobrovova Z., Semecky V., Vavrova J., Holeckova M., Palicka V., Mazurova Y., Nachtigal P. Cardiac biomarkers in a model of acute catecholamine cardiotoxicity. Hum. Exp. Toxicol. 2009, 28:631-640.
32. Mladenka P., Kalinowski D.S., Haskova P., Bobrovova Z., Hrdina R., Simunek T., Nachtigal P., Semecky V., Vavrova J., Holeckova M., Palicka V., Mazurova Y., Jansson P.J., Richardson D.R. The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity. Chem. Res. Toxicol. 2009, 22:208-217.
33. Mladenka P., Simunek T., Hubl M., Hrdina R. The role of reactive oxygen and nitrogen species in cellular iron metabolism. Free Radic. Res. 2006, 40:263-272.
34. Molina-Holgado F., Gaeta A., Francis P.T., Williams R.J., Hider R.C. Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. J. Neurochem. 2008, 105:2466-2476.
35. Morales N.P., Yamanont P., Jirasomprasert T., Wilairat P., Chantharaksri U., Chuncharunee S., Fucharoen S. Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers. Int. J. Clin. Pharmacol. Ther. 2009, 47:358-364.
36. Olivieri N.F., Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89:739-761.
37. Popelova O., Sterba M., Haskova P., Simunek T., Hroch M., Guncova I., Nachtigal P., Adamcova M., Gersl V., Mazurova Y. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br. J. Cancer 2009, 101:792-802.
38. Popelova O., Sterba M., Simunek T., Mazurova Y., Guncova I., Hroch M., Adamcova M., Gersl V. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. J. Pharmacol. Exp. Ther. 2008, 326:259-269.
39. Rajadurai M., Prince P.S. Preventive effect of naringin on isoproterenol-induced cardiotoxicity in Wistar rats: an in vivo and in vitro study. Toxicology 2007, 232:216-225.
40. Reddy B.R., Wynne J., Kloner R.A., Przyklenk K. Pretreatment with the iron chelator desferrioxamine fails to provide sustained protection against myocardial ischaemia-reperfusion injury. Cardiovasc. Res. 1991, 25:711-718.
41. Reif D.W. Ferritin as a source of iron for oxidative damage. Free Radic. Biol. Med. 1992, 12:417-427.
42. Remiao F., Carvalho M., Carmo H., Carvalho F., Bastos M.L. Cu2+-induced isoproterenol oxidation into isoprenochrome in adult rat calcium-tolerant cardiomyocytes. Chem. Res. Toxicol. 2002, 15:861-869.
43. Repetto G., del Peso A., Zurita J.L. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat. Protoc. 2008, 3:1125-1131.
44. Seely D.M., Wu P., Mills E.J. EDTA chelation therapy for cardiovascular disease: a systematic review. BMC Cardiovasc. Disord. 2005, 5:32.
45. Simunek T., Boer C., Bouwman R.A., Vlasblom R., Versteilen A.M., Sterba M., Gersl V., Hrdina R., Ponka P., de Lange J.J., Paulus W.J., Musters R.J. SIH-a novel lipophilic iron chelator-protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J. Mol. Cell. Cardiol. 2005, 39:345-354.
46. Simunek T., Sterba M., Holeckova M., Kaplanova J., Klimtova I., Adamcova M., Gersl V., Hrdina R. Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. Biometals 2005, 18:163-169.
47. Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 2009, 61:154-171.
48. Simunek T., Sterba M., Popelova O., Kaiserova H., Adamcova M., Hroch M., Haskova P., Ponka P., Gersl V. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. Br. J. Pharmacol. 2008, 155:138-148.
49. Spallarossa P., Garibaldi S., Altieri P., Fabbi P., Manca V., Nasti S., Rossettin P., Ghigliotti G., Ballestrero A., Patrone F., Barsotti A., Brunelli C. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J. Mol. Cell. Cardiol. 2004, 37:837-846.
50. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 2007, 30:244-250.
51. Summers M.R., Jacobs A., Tudway D., Perera P., Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br. J. Haematol. 1979, 42:547-555.
52. Terman A., Brunk U.T. Oxidative stress, accumulation of biological 'garbage', and aging. Antioxid. Redox Signal. 2006, 8:197-204.
53. Valko M., Morris H., Cronin M.T. Metals, toxicity and oxidative stress. Curr. Med. Chem. 2005, 12:1161-1208.
54. van der Kraaij A.M., van Eijk H.G., Koster J.F. Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. Circulation 1989, 80:158-164.
55. Voogd A., Sluiter W., van Eijk H.G., Koster J.F. Low molecular weight iron and the oxygen paradox in isolated rat hearts. J. Clin. Invest. 1992, 90:2050-2055.
56. Wang H., Joseph J.A. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic. Biol. Med. 1999, 27:612-616.
57. Watanabe B.I., Limm W., Suehiro A., Suehiro G., Premaratne S., McNamara J.J. Failure of deferoxamine to reduce myocardial infarct size in a primate model of ischemia-reperfusion injury. J. Surg. Res. 1993, 55:537-542.
58. Wood J.C. Cardiac iron across different transfusion-dependent diseases. Blood Rev. 2008, 22(Suppl. 2):S14-S21.
59. Wood J.C. Cardiac complications in thalassemia major. Hemoglobin 2009, 33(Suppl. 1):S81-S86.
60. Wood J.C., Enriquez C., Ghugre N., Otto-Duessel M., Aguilar M., Nelson M.D., Moats R., Coates T.D. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann. N. Y. Acad. Sci. 2005, 1054:386-395.
61. Yamanaka S., Tatsumi T., Shiraishi J., Mano A., Keira N., Matoba S., Asayama J., Fushiki S., Fliss H., Nakagawa M. Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J. Am. Coll. Cardiol. 2003, 41:870-878.